A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of AL002 in Participants With Early Alzheimer’s Disease

– Diagnosis of Early AD including evidence of brain amyloidosis by CSF or PET

– MMSE score ≥ 22 points, CDR Global Score of 0.5 – 1.0, and RBANS score on the DMI ≤85.

– Study partner who consents to study participation and who cares for/visits the
participant at least 10 hours a week

– Written informed consent must be obtained and documented (from the participant or,
where jurisdictions allow it, from their legal decision maker).

Exclusion Criteria:

– Dementia due to a condition other than AD including, but not limited to, FTD,
Parkinson’s disease, dementia with Lewy bodies, Huntington disease, or vascular
dementia.

– Known history of severe allergic, anaphylactic, or other hypersensitivity reactions to
chimeric, human, or humanized antibodies or fusion proteins.

– Current uncontrolled hypertension, diabetes mellitus or thyroid disease. Clinically
significant heart disease, liver disease or kidney disease.

– History or evidence of clinically significant brain disease other than AD.

– Females who are pregnant or breastfeeding, or planning to conceive within the study
period.

– Any experimental vaccine or gene therapy.

– History of unresolved cancer.

– Current use of anticoagulant medications.

– Residence in a skilled nursing facility, convalescent home, or long term care facility
at screening; or requires continuous nursing care.